Honeybees are vital to global food security, yet colony collapse threatens ecosystems and agriculture worldwide.   Discover ...

Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management, including CEO Ilan Hadar, will attend the ...

Arrowhead Pharmaceuticals today announced interim results from two Phase I/IIa clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutics being ...

Arrowhead’s stock rose 6% on market open after the announcement though continued to rise throughout the day.

Arrowhead Pharmaceuticals recently reported interim Phase 1/2a data showing its RNAi obesity candidates ARO-INHBE and ARO-ALK7 reduced visceral and liver fat and enhanced weight loss versus ...

SenseUP’s platform tech could overcome the cost and stability hurdles holding back RNAi-based crop protection, claims the ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...

Please provide your email address to receive an email when new articles are posted on . RNA therapeutics lowered all-cause mortality, increased 6-minute walk distance and improved quality of life. RNA ...

Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...

BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million ...

It was not until 2018 that the US FDA approved the first therapy developed using the technique. Since then, there’s been a steady, but slow, number of RNAi treatments coming into the market. The ROBO ...